16/05/2018 19:19:32

CORRECTING AND REPLACING: Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update

ORLANDO, Fla., May 16, 2018 (GLOBE NEWSWIRE) -- In a release issued earlier today by Hemispherx Biopharma, Inc. (NYSE American:HEB) with the same headline, the net loss from operations was incorrect in the fourth paragraph. It should say $0.07 per share, not $0.70 per share. The corrected release follows.

Hemispherx Biopharma, Inc. (NYSE American:HEB), an advanced specialty pharmaceutical company engaged in the treatment of serious and debilitating disorders through the development of its immunology products Ampligen® and Alferon®, today announced its financial results for the first quarter ended March 31, 2018.

“We made significant progress in the quarter that just ended, including significant improvements to our balance sheet, the production of the equivalent of more than 8,500 vials of Ampligen at our contract fill and finish manufacturer, the expansion of our Ampligen supply agreements for early access programs in Canada and Europe under the management of myTomorrows, and the continuation of our plans to start advanced clinical trials of Ampligen as a single agent and a combination immuno-oncology therapy,” said Thomas K. Equels, Hemispherx’s chief executive officer.

“During the quarter we added to our cash by booking Ampligen sales, the sale/leaseback of our manufacturing facility, the sale of non-strategic real estate, and the exercise of warrants and the sale of common stock,” he continued. “We believe that this will enable us to meet the current and anticipated needs of our commercial channels and clinical study programs, as we work with the FDA to identify a path toward approval for Ampligen for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” 

First Quarter 2018 Financial Highlights

As of March 31, 2018, Hemispherx had $4.6 million in cash and cash equivalents, compared to $2.1 million at December 31, 2017. Cash used in operations was $2.5 million for the three months ended March 31, 2018, compared to $3.0 million in the same quarter in 2017. The net loss from operations was $2.7 million, or $0.07 per share, for the first quarter of 2018, compared to a net loss of $2.8 million, or $0.11 per share, for the first quarter of 2017.

A

bout Hemispherx Biopharma

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for the treatment of serious and debilitating disorders. Hemispherx's flagship products include the FDA-approved drug Alferon N Injection® and the Argentina-approved drug rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is a double-stranded RNA being developed for globally important diseases and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Because rintatolimod has not been designated safe and effective by the FDA for general use, it is legally available in the United States only through clinical trials. However, Ampligen® has been approved in Argentina for ME/CFS and the company is working toward legal access in other countries where early access programs exist for serious diseases with unmet medical needs, such as ME/CFS. Ampligen® is the only therapy approved anywhere in the world for ME/CFS. An Ampligen® Early Access Program (EAP) approval has also been obtained for therapeutic use in the Netherlands for pancreatic cancer.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Contact

Hemispherx Biopharma

Phone Number: 800-778-4042

Email: IR@hemispherx.net

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
19 Sep
 
Jeg har været med som skribent her på EI siden 2012 og jeg har haft mange gode øjeblikke ved at være..
62
20 Sep
VWS
Vestas aktien fylder en del i min portefølje, hvorfor jeg følger den tæt. Jeg var dog selv tidligere..
35
22 Sep
DANSKE
Er det ikke tænkevækkende i disse dage at være vidne til vores politikere, der berettiget forarges o..
31
20 Sep
 
Danmark forærer 12mia kr væk til svindlere - med hjælp fra et par fordrukne ansatte i skat. Så stort..
23
23 Sep
DANSKE
Danske har intet lært. Ikke af finanskrisen, ikke af skattely sager, ikke af panama sager. De har ty..
22
24 Sep
TEVA
Dansk Aktionaerforening gjorde et lille scoop og fik Kaare Schultz til at deltage i InvestorDagen i ..
19
24 Sep
VWS
MHI Vestas turbine platform can scale up to GE's 12 MW rival: CEO https://www.reuters.com/article/us..
18
20 Sep
DANSKE
Erhversministeren mener at hvidvaskskandalen er "en af de største skandaler i danmarkshistorien" og ..
16
21 Sep
DANSKE
Desværre har pressen og visse politikere dømt i en sag for at mele deres kager.  Hvis man har fulgt ..
14
20 Sep
DANSKE
MEN DER ER INGEN SAG!  Det er IKKE Danske Banks opgave at forhindre pengeudførsel fra Rusland !  Der..
14

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Diagnostic Superiority and Equivalence to Biopsy: a Study Confirms the Clinical Value of ShearWave® Elastography (SWE™) for the Non-Invasive Evaluation of Liver Fibrosis
2
Payment Security Compliance drops for the first time in six years, states Verizon’s 2018 Payment Security Report
3
PCG Advisory Group Co-Sponsored Family Office Event Presented by Morgan Creek Capital and BlockWorks Group
4
Motif Bio Reports Half-Year 2018 Financial Results and Operational Progress
5
Recall Studios Will Host Shareholder Call, Tuesday, September 25th at 11am EST

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 September 2018 16:47:34
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180919.1 - EUROWEB4 - 2018-09-25 17:47:34 - 2018-09-25 16:47:34 - 1000 - Website: OKAY